Sagar S. Patel, MD, discusses data from a retrospective analysis of Orca-T and PTCy for hematologic malignancies and its implications for the field.

Chronic graft-versus-host disease (GVHD) occurs in up to 70% of patients who have undergone an allogeneic hematopoietic stem cell transplant and is the main cause of late, non-relapse mortality.1 It [...

Alfred L. Garfall, MD, discusses the role of ide-cel in patients with multiple myeloma following suboptimal responses to upfront auto-HCT.

Orca-T improved OS vs post-transplant cyclophosphamide in a retrospective analysis of patients with hematologic malignancies.

Cilta-cel led to rapid and deep MRD negativity in patients with lenalidomide-refractory multiple myeloma.

Orca-T with HSCT-RIC displayed robust and early donor myeloid and T-cell engraftment in patients with advanced hematologic malignancies.